EGFR and non-small cell lung carcinoma: A phase I/II clinical trial of IRDye800CW-nimotuzumab46 in patients with resectable non-small cell lung cancer concluded that IRDye800CW conjugated to nimotuzumab was safe and did not exhibit toxicities commonly associated with EGFR targeting antibodies47.